Glycemic variability from switching to steady state in patients treated with long-acting insulin: randomised crossover study

Glycemic variability from switching to steady state in patients treated with long-acting insulin: randomised crossover study - Glycemic variability from switching to steady state in patients treated with long-acting insulin

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032856

Enrollment

Registered

2018-06-04

Start date

2018-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

Upon admission, insulin glargine 300 U/ml is continued for 6 days with the same dose. FreeStyle Libre Pro is worn on fifth day of the same dose insulin glargine 300 U/ml. Insulin glargine 300 U/ml is

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: type 2 diabetic patients treated with long-acting insulin in basal insulin therapy for 3 month or longer

Exclusion criteria

Exclusion criteria: severe renal dysfunction (serum creatinine level over 2.0 mg/dL) judged to be unsuitable for participation for medical reasons

Design outcomes

Primary

Measure	Time frame
Mean of daily difference 1 (MODD1)	—

Secondary

Measure	Time frame
Multiple continuous overlapping net glycemic action 24 (MCONGA24) (original index) Standard deviation of daily difference (SDODD) (original index) Mean of daily difference (MODD) (day before switching vs. first day, second day vs. third day, fifth day vs. sixth day) continuous overlapping net glycemic action 24 (CONGA24) (day before switching vs. first day, second day vs. third day, fifth day vs. sixth day) Mean absolute glucose (MAG) during evaluation duration (for 7 days) Glycemic variability percentage (GVP) during evaluation duration (for 7 days) Mean glucose level during evaluation duration (for 7 days) Standard deviation (SD) during evaluation duration (for 7 days) Coefficient of variation (CV) during evaluation duration (for 7 days) We investigated the relationship between glycemic diurnal variation (MAG, GVP, mean glucose level, and SD) and glycemic daily variation (MODD and CONGA24) using simulated CGM profiles measured every 15 minute for 24 hours.	—

Measure

Time frame

Multiple continuous overlapping net glycemic action 24 (MCONGA24) (original index) Standard deviation of daily difference (SDODD) (original index) Mean of daily difference (MODD) (day before switching vs. first day, second day vs. third day, fifth day vs. sixth day) continuous overlapping net glycemic action 24 (CONGA24) (day before switching vs. first day, second day vs. third day, fifth day vs. sixth day) Mean absolute glucose (MAG) during evaluation duration (for 7 days) Glycemic variability percentage (GVP) during evaluation duration (for 7 days) Mean glucose level during evaluation duration (for 7 days) Standard deviation (SD) during evaluation duration (for 7 days) Coefficient of variation (CV) during evaluation duration (for 7 days) We investigated the relationship between glycemic diurnal variation (MAG, GVP, mean glucose level, and SD) and glycemic daily variation (MODD and CONGA24) using simulated CGM profiles measured every 15 minute for 24 hours.

—

Countries

Japan

Contacts

Public ContactSoichi Takeishi

Inuyama Chuo General Hospital Diabetes

souichi19811225@yahoo.co.jp0568-62-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026